Table 1. Baseline characteristics.
| Variables | Unmatched | Propensity score matched | |||||
| Complete group (n = 445) |
Incomplete group (n = 818) |
P-value | Complete group (n = 409) |
Incomplete group (n = 409) |
P-value | ||
| Data are presented as n (%) or median (interquartile range). | |||||||
| Demographics | |||||||
| Age, yrs | 79.9 (77–83.8) | 80 (77.3–83.1) | 0.80 | 79.9 (77–83.7) | 80 (77.4–83.6) | 0.71 | |
| Female | 179 (40.2%) | 320 (39.1%) | 0.70 | 162 (39.6%) | 152 (37.2%) | 0.47 | |
| Medical history | |||||||
| Hypertension | 347 (78.0%) | 595 (72.7%) | 0.04 | 315 (77.0%) | 316 (77.3%) | 0.93 | |
| Hyperlipidemia | 216 (48.5%) | 366 (44.7%) | 0.20 | 195 (47.7%) | 182 (44.5%) | 0.36 | |
| Diabetes mellitus | 140 (31.5%) | 274 (33.5%) | 0.46 | 128 (31.3%) | 154 (37.7%) | 0.06 | |
| Peripheral arterial disease | 44 (9.9%) | 114 (13.9%) | 0.04 | 42 (10.3%) | 43 (10.5%) | 0.91 | |
| Prior acute myocardial infarction | 70 (15.7%) | 162 (19.8%) | 0.07 | 67 (16.4%) | 62 (15.2%) | 0.63 | |
| Congestive heart failure | 20 (4.7%) | 35 (5.2%) | 0.71 | 20 (5.1%) | 19 (5.2%) | 0.94 | |
| Chronic kidney disease | 17 (9.7%) | 33 (10.9%) | 0.67 | 17 (9.7%) | 22 (11.5%) | 0.58 | |
| Peptic ulcer | 6 (3.3%) | 16 (5.3%) | 0.30 | 6 (3.3%) | 12 (6.3%) | 0.19 | |
| Prior percutaneous coronary intervention | 85 (19.1%) | 105 (12.8%) | < 0.01 | 68 (16.6%) | 67 (16.4%) | 0.92 | |
| Prior coronary artery bypass grafting | 35 (7.9%) | 60 (7.3%) | 0.73 | 27 (6.6%) | 29 (7.1%) | 0.78 | |
| Prior bleeding | 22 (4.9%) | 65 (8.0%) | 0.04 | 20 (4.9%) | 29 (7.1%) | 0.16 | |
| Malignancy | 47 (10.6%) | 81 (9.9%) | 0.71 | 45 (11.0%) | 34 (8.3%) | 0.19 | |
| Clinical status | |||||||
| Type of acute coronary syndrome | |||||||
| ST-segment elevation myocardial infarction | 167 (37.5%) | 468 (57.2%) | < 0.01 | 159 (38.9%) | 163 (39.9%) | 0.77 | |
| Non-ST-segment elevation acute coronary syndrome | 278 (62.5%) | 350 (42.8%) | 250 (61.1%) | 246 (60.2%) | |||
| Killip classification ≥ 2 | 120 (27.9%) | 171 (21.8%) | 0.02 | 105 (25.7%) | 104 (25.4%) | 0.94 | |
| Hemoglobin, g/dL | 13.3 (12–14.4) | 13.1 (11.8–14.3) | 0.21 | 13.3 (12–14.5) | 13.06 (11.9–14.3) | 0.21 | |
| Creatinine, mg/dL | 1.0 (0.8–1.2) | 1.0 (0.8–1.2) | 0.53 | 1.0 (0.8–1.2) | 1.0 (0.8–1.2) | 0.99 | |
| Left ventricular ejection fraction, % | 55 (40–60) | 53 (40–60) | 0.54 | 55 (40–60) | 55.5 (45–60) | 0.27 | |
| Procedures | |||||||
| Percutaneous transluminal coronary angioplasty | 8 (1.8%) | 56 (6.9%) | < 0.01 | 8 (2.0%) | 7 (1.7%) | 0.79 | |
| Drug-eluting stent | 174 (39.1%) | 264 (32.3%) | 0.01 | 155 (37.9%) | 140 (34.2%) | 0.27 | |
| Thrombolysis | 4 (0.9%) | 8 (1.0%) | 0.89 | 4 (1.0%) | 4 (1.0%) | 1.00 | |
| Medications at discharge | |||||||
| Aspirin | 439 (98.7%) | 798 (97.6%) | 0.19 | 404 (98.8%) | 401 (98.0%) | 0.40 | |
| Clopidogrel | 404 (90.8%) | 751 (91.8%) | 0.53 | 377 (92.2%) | 385 (94.1%) | 0.27 | |
| Ticagrelor | 23 (5.2%) | 29 (3.6%) | 0.17 | 16 (3.9%) | 10 (2.4%) | 0.23 | |
| Prasugrel | 5 (1.1%) | 7 (0.9%) | 0.64 | 5 (1.2%) | 3 (0.7%) | 0.48 | |
| Oral anticoagulation | 43 (9.7%) | 66 (8.1%) | 0.34 | 35 (8.6%) | 26 (6.4%) | 0.23 | |
| Angiotensin-converting enzyme inhibitor/Angiotensin II receptor blocker |
347 (78.0%) | 565 (69.1%) | < 0.01 | 313 (76.5%) | 311 (76.1%) | 0.87 | |
| Beta-blocker | 339 (76.2%) | 644 (78.7%) | 0.30 | 309 (75.6%) | 320 (78.2%) | 0.36 | |
| Statins | 394 (88.5%) | 729 (89.1%) | 0.75 | 365 (89.2%) | 365 (89.2%) | 1.00 | |